About |
PriorAuthAppeal helps US patients fight prior-authorization denials for GLP-1 weight-loss medications. The service is built on a curated database of the major US insurers' published GLP-1 coverage policies (UnitedHealthcare, Aetna, Cigna, Anthem, BCBS, Kaiser, Humana, and others) and produces a personalized, citation-grounded appeal letter in approximately 30 minutes.
Patients submit their denial letter and basic clinical context. They receive an emailed appeal letter, a one-page summary for the physician's office, and a checklist of supporting documents. Each letter cites the patient's specific insurer's published policy criteria and references current clinical guidelines (AACE 2023, ADA 2025) and federal appeal-rights statutes (ACA Sections 1557 and 2719, ERISA Section 503).
Pricing is $59 flat per letter with a money-back guarantee if the patient's prescribing physician declines to sign the letter as drafted. There is no subscription, no consultation fee, and the service does not communicate with insurers on the patient's behalf — the physician remains the medical decision-maker.
PriorAuthAppeal currently supports policies for the ten largest US insurers and the four FDA-approved GLP-1 medications most affected by denial activity: Wegovy (semaglutide 2.4 mg), Ozempic (semaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide).
The service was launched in 2026 by Omer Pines and operates from priorauthappeal.com.